Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Receivables (2018 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Change in Receivables for 8 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 60.79% to $33.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.0 million, a 8.82% decrease, with the full-year FY2025 number at $31.0 million, down 8.82% from a year prior.
  • Change in Receivables was $33.8 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$5.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $33.8 million in Q4 2025 to a low of -$10.1 million in Q1 2025.
  • A 5-year average of $5.3 million and a median of $2.3 million in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: tumbled 955.56% in 2022, then soared 7700.0% in 2023.
  • Ultragenyx Pharmaceutical's Change in Receivables stood at $3.1 million in 2021, then surged by 196.25% to $9.1 million in 2022, then tumbled by 108.69% to -$790000.0 in 2023, then soared by 2763.54% to $21.0 million in 2024, then surged by 60.79% to $33.8 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Change in Receivables are $33.8 million (Q4 2025), -$5.4 million (Q3 2025), and $12.7 million (Q2 2025).